202 related articles for article (PubMed ID: 18176107)
1. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells.
Llobet D; Eritja N; Encinas M; Sorolla A; Yeramian A; Schoenenberger JA; Llombart-Cussac A; Marti RM; Matias-Guiu X; Dolcet X
Anticancer Drugs; 2008 Feb; 19(2):115-24. PubMed ID: 18176107
[TBL] [Abstract][Full Text] [Related]
2. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death.
Fernández Y; Miller TP; Denoyelle C; Esteban JA; Tang WH; Bengston AL; Soengas MS
J Biol Chem; 2006 Jan; 281(2):1107-18. PubMed ID: 16278210
[TBL] [Abstract][Full Text] [Related]
3. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
5. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Ling YH; Liebes L; Zou Y; Perez-Soler R
J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Yerlikaya A; DoKudur H
Mol Biol (Mosk); 2010; 44(5):859-66. PubMed ID: 21090173
[TBL] [Abstract][Full Text] [Related]
8. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
9. A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells.
Ding WX; Ni HM; Chen X; Yu J; Zhang L; Yin XM
Mol Cancer Ther; 2007 Mar; 6(3):1062-9. PubMed ID: 17363499
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
11. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
Zou W; Yue P; Lin N; He M; Zhou Z; Lonial S; Khuri FR; Wang B; Sun SY
Clin Cancer Res; 2006 Jan; 12(1):273-80. PubMed ID: 16397052
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Bazzaro M; Lee MK; Zoso A; Stirling WL; Santillan A; Shih IeM; Roden RB
Cancer Res; 2006 Apr; 66(7):3754-63. PubMed ID: 16585202
[TBL] [Abstract][Full Text] [Related]
13. Effects of antioxidants and caspase-3 inhibitor on the phenylethyl isothiocyanate-induced apoptotic signaling pathways in human PLC/PRF/5 cells.
Wu SJ; Ng LT; Lin CC
Eur J Pharmacol; 2005 Aug; 518(2-3):96-106. PubMed ID: 16054126
[TBL] [Abstract][Full Text] [Related]
14. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Yu J; Tiwari S; Steiner P; Zhang L
Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
[TBL] [Abstract][Full Text] [Related]
15. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
An WG; Hwang SG; Trepel JB; Blagosklonny MV
Leukemia; 2000 Jul; 14(7):1276-83. PubMed ID: 10914553
[TBL] [Abstract][Full Text] [Related]
16. Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction.
Supinski GS; Vanags J; Callahan LA
Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L994-L1001. PubMed ID: 19376888
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
Yang X
Biomed Pharmacother; 2012 Dec; 66(8):607-11. PubMed ID: 23089480
[TBL] [Abstract][Full Text] [Related]
18. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
[TBL] [Abstract][Full Text] [Related]
20. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
